AAN 2025: Sanofi's tolebrutinib likely to be first BTK inhibitor for the treatment of MS
During the Clinical Trials Plenary Session, Sanofi announced that tolebrutinib delayed the time to onset of six-month confirmed disability progression (CDP) by 31% compared to placebo in patients with nrSPMS, meeting the primary endpoint of the HERCULES trial. In addition, tolebrutinib met some of its secondary endpoints where it delayed the time to three-month CDP by 24% compared to placebo, and significantly lowered the annualised rate of new or enlarging T2 lesions versus placebo by 38%. While a lower proportion of participants in the tolebrutinib group showed progression in the Timed 25-Foot Walk, tolebrutinib did not differentiate from placebo in the 9-hole peg test.
During the Plenary Session, Sanofi also reported that tolebrutinib failed to meet the primary endpoint of reducing annualised relapse rate over teriflunomide in patients with RMS in the GEMINI studies. A pooled analysis of GEMINI 1 and GEMINI 2 for a key secondary endpoint, not controlled for multiplicity, showed that tolebrutinib delayed the time to onset of six-month confirmed disability worsening by 29% versus teriflunomide. But the number of new Gd-enhancing T1 lesions was higher in the tolebrutinib arm and the number of new or enlarging T2 lesions was similar between both treatment arms. The results of the GEMINI trials follow Sanofi's decision, in January 2025, to remove its tolebrutinib RMS programme from its pipeline, focusing on progressive forms of MS only. In addition to development in nrSPMS per the HERCULES trial, there is an ongoing Phase III study to investigate the efficacy of tolebrutinib compared to placebo in delaying disease progression in patients with primary progressive MS (PERSEUS). Tolebrutinib was generally well-tolerated in the HERCULES, GEMINI 1, and GEMINI 2 trials. Liver enzyme elevations, defined by greater than three times the upper limit of normal, were observed in 4.0% of tolebrutinib patients in the HERCULES trial and 5.6% of tolebrutinib patients in the GEMINI studies. However, safety concerns have been previously raised. In June 2022, the US Food and Drug Administration (FDA) placed a partial clinical hold on tolebrutinib due to reported cases of drug-liver induced injury in patients who received the drug during clinical trials. Key opinion leaders (KOLs) previously interviewed by leading data and analytics company GlobalData stated that should tolebrutinib receive approval, it is likely to be accompanied by a boxed warning and risk evaluation and mitigation strategies.
The majority of marketed disease-modifying therapies for MS target peripheral inflammation for reducing relapses, but few possess neuroprotective effects and, as such, have insufficient impact on the underlying neurologic deterioration caused by MS. The MS therapeutics market is heavily skewed towards reducing relapses in patients with RMS. KOLs previously interviewed by GlobalData stressed the need for a new product that could prevent disease progression. The gravity of this unmet need is highlighted by the number of BTK inhibitors in clinical development for MS. According to GlobalData's drug database, there are three BTK inhibitors in Phase III development. Tolebrutinib will compete with Genentech/Roche's fenebrutinib, Novartis' remibrutinib, and InnoCare Pharma's orelabrutinib. Last month, Sanofi announced tolebrutinib's US regulatory submission was accepted for priority review, and the target action date for the FDA decision for tolebrutinib is 28 September 2025. If approved, tolebrutinib would be the first and only BTK inhibitor to treat both non-relapsing SPMS and slow disability accumulation.
"AAN 2025: Sanofi's tolebrutinib likely to be first BTK inhibitor for the treatment of MS" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
How xAI Is Running on Former Google (GOOGL) Employees
So far in 2025, two founding members of Elon Musk's artificial intelligence company xAI have left the team. Indeed, Christian Szegedy left in May, and Igor Babuschkin departed this week. Notably, both had previously worked at Google (GOOGL), and xAI continues to hire heavily from the tech giant, with at least 40 ex-Google staffers joining since its founding in 2023, according to The Information. It is worth noting that many of these new hires had worked on cutting-edge projects, such as Google DeepMind's Gemini models. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Now at xAI, they're helping build Grok 4, which Musk says outperforms similar AI models from OpenAI, Meta (META), and Google. This movement of talent shows just how frequently researchers are switching between top AI firms. Although some xAI employees have left for OpenAI, including co-founder Kyle Kosic and infrastructure engineering head Uday Rudarraju, there hasn't been a noticeable wave of defections to Google, Microsoft (MSFT), or Meta. A likely reason is that xAI is still a young company, and many employees' stock options haven't fully vested yet. xAI is also known for its intense work pace, with some teams reportedly working all seven days of the week. While that might drain some employees, others are said to be motivated by the company's mission and are eager to contribute. Nevertheless, the company has been facing some integration issues after merging with social media platform X in March. In fact, the two companies still operate somewhat separately, with different internal systems and even separate Slack accounts. As a result of these limitations, some employees have resorted to using Signal group chats instead to coordinate their work. What Is the Prediction for Tesla Stock? When it comes to Elon Musk's companies, most of them are privately held. However, retail investors can invest in his most popular company, Tesla (TSLA). Turning to Wall Street, analysts have a Hold consensus rating on TSLA stock based on 14 Buys, 15 Holds, and eight Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average TSLA price target of $307.23 per share implies 6.5% downside risk.
Yahoo
8 hours ago
- Yahoo
Your Daily Work Horoscope for August 16, 2025
Your Daily Work Horoscope for August 16, 2025. Discover your Daily Work Horoscope for each zodiac sign here. Aries You are soon to be recruited or prepared for more responsibility so look surprised. You are held in much higher esteem than you think, and now is the time when your worth will start showing. Taurus Lie low and just let the big workplace drama fizzle out on its own. You will be affected, but you can't play a meaningful role just now. It's best if you can work at home or with one person. Gemini You need to pare back spending even further and maybe cut into future spending as well. Growth can wait until you feel stable, no matter what the others on your team may say. Cancer You and your team have the stamina to finish almost any task on time and should attract positive attention. Try not to soak up all the kudos for yourself, though you definitely deserve a big share. Leo You may need to persuade a supervisor to sign off on a change you know needs to be made. They might not agree to all your terms, but you're famous for getting by with what you have. Find out what the cards have in store for you with your 2022 Tarot Reading. Virgo Now is an excellent time to inquire about that raise or promotion or special treatment you know you deserve. People will be feeling generous, and you should be able to spin your side well. Libra It's time once again to listen and learn. Everyone has a different take on recent events, but if you add them all up and calculate the average, you'll soon find that you know the truth. Scorpio Your social skills are incredibly hot right now, and your clients will especially love their time with you. If you need to ask for extensions or changes, now is the time to make your pitch. Sagittarius You have a lot of brainwork ahead of you and that suits you just fine. It might take quite a bit of trial and error before you hit on the right way to go about it, but once you do it will go quickly. Capricorn You have plenty of work to do, as always, but you should try to add lots of different tasks and projects rather than throwing yourself into a single endeavor. Flexibility and variety are key. Aquarius Your initial resistance to the change in plans or the new idea should be taken as a sign that you need to consider it more thoroughly. There's one coworker whose judgment you should trust. Pisces Stay focused as much as possible. You have responsibilities that need to come before working on pet projects or brainstorming those new ideas you know you have squirming in your brain. Are you meant to be? Find out with our Love Compatibility Report! Solve the daily Crossword
New York Post
9 hours ago
- New York Post
Winklevoss twins reveal more details in Gemini IPO filing as crypto-friendly Trump boosts investor demand
Gemini's revenue fell and losses widened in the first half of 2025, the cryptocurrency exchange said in a US IPO filing, joining a wave of digital-asset firms seeking to tap public markets. Terms of the offering were not disclosed in the filing, made public on Friday. The company reported a net loss of $282.5 million on a total revenue of $68.6 million in the six months ended June 30, compared with a net loss of $41.4 million on a revenue of $74.3 million year earlier. Advertisement 3 Tyler and Cameron Winklevoss attend the signing ceremony for the GENIUS Act at the White House last month. Getty Images US IPO activity has rebounded in recent months following a slowdown earlier this year caused by uncertainty over trade policy changes, with several new listings drawing strong investor demand. Digital asset companies have also featured prominently in the IPO market in recent months, including blockbuster debuts from stablecoin issuer Circle and cryptocurrency exchange Bullish. Advertisement Bullish's debut on Wednesday made it the second listed cryptocurrency exchange in the country after Coinbase Global. Gemini will become the third public crypto exchange once it goes public. 'The question for investors regarding Gemini revolves around the business mix and moat of trading versus custody, how they differentiate on trust and growth, and what they do that Coinbase can't copy by Tuesday,' said Michael Ashley Schulman, partner and CIO at Running Point Capital. Gemini said it will use IPO proceeds for general corporate purposes and to repay all or part of its third-party debt. The exchange also supports stablecoins on its platform, a segment that has drawn attention following last month's signing of the GENIUS Act, a new US law establishing a regulatory framework for stablecoins. Advertisement 3 The GENIUS Act is a new US law establishing a regulatory framework for stablecoins. AFP via Getty Images Gemini issues the Gemini Dollar (GUSD), a stablecoin pegged 1:1 to the US dollar. The company, which also supports more than 70 cryptocurrencies and operates in over 60 countries, confidentially filed for an IPO in June. Gemini, which was founded in 2014 by billionaire twins Tyler and Cameron Winklevoss, plans to list on Nasdaq under the ticker symbol 'GEMI.' Goldman Sachs and Citigroup are acting as lead bookrunners. Advertisement The Winklevoss twins rose to prominence after suing Facebook, and its CEO Mark Zuckerberg, alleging he stole their idea for the social network. They settled in 2008 for cash and Facebook stock. 3 Executives of cryptocurrency exchange Bullish celebrate at New York Stock Exchange on Wednesdday. REUTERS Regulatory boost Regulatory clarity under the Trump administration, rising institutional adoption, and increasing ETF inflows have bolstered investor confidence and helped integrate crypto into mainstream finance. In a watershed moment for the industry, Coinbase became the first blockchain-focused company to join the S&P 500 earlier this year. Block, which facilitates bitcoin purchases, joined the index in July. The shift marks a turnaround for an industry that spent more than a decade under heavy regulatory scrutiny worldwide. 'We've seen a shift from speculation to sustainability. Institutional investors are looking for proof points – real clients, regulated products, and long-term market alignment. This is how the sector matures, and it will likely set the stage for other crypto firms keen to list their shares,' said Nick Jones, founder of crypto firm Zumo.
